SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 1998
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:(516-286-5800)
N/A
(Former name or former address, if changed since last report.)
<PAGE>
ITEM 5. Other Material Events
On July 29, 1998 Mr. Edward Fine President and Chief Executive Officer
resigned from the Company. He was replaced on an interim basis by Mr. Jonathan
Rosen, a current member of the Board of Directors. Mr. Fine has agreed to remain
with the Company as a consultant . EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: August 11, 1998
Exhibit:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Jonathan Rosen
Jonathan Rosen
President, Chief Executive Officer
Dated: August 11, 1998
